NYXH

+ Watchlist + Portfolio

Nyxoah SA

Regulated industry Physical productsTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $1.33
52-Week Range: $1.26 – $6.88
Market Cap: $138.50M
P/E (TTM): —
EPS (TTM): -2.56
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: 1.41
PEG Ratio: —
Return on Equity: -122.68%
Return on Assets: -36.87%
Gross Margin: 60.19%
Operating Margin: -268.25%
Profit Margin: 0.00%
Current Ratio: 2.38
Debt/Equity: 0.72
Total Debt: $59.99M
Free Cash Flow: $-46.06M
Revenue Growth: 472.80%
Earnings Growth: —
Enterprise Value: $98.30M

NYXH Income statement, annual periods, in EUR
EUR	FY2022	FY2023	FY2024	FY2025
Revenue	$3.08M	$4.35M	$4.52M	$10.02M
Cost of Revenue	$1.15M	$1.66M	$1.55M	$3.69M
Gross Profit	$1.93M	$2.69M	$2.97M	$6.33M
Research & Development	$15.86M	$26.65M	$34.33M	$42.82M
Selling, General & Admin	$17.94M	$20.64M	$27.18M	$46.44M
Operating Expenses	$34.43M	$47.79M	$61.78M	$89.27M
Operating Income	-$32.50M	-$45.10M	-$58.81M	-$82.94M
EBITDA	-$27.89M	-$42.08M	-$52.83M	-$82.74M
Pretax Income	-$30.06M	-$44.66M	-$56.43M	-$89.08M
Income Tax	$1.17M	-$1.45M	$2.80M	$1.01M
Net Income	-$31.23M	-$43.21M	-$59.24M	-$90.08M
Diluted EPS	-1.21	-1.54	-1.81	-2.36
Diluted Shares	25.83M	27.97M	32.75M	38.11M

NYXH Balance Sheet statement, annual periods, in EUR
EUR	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$17.89M	$21.61M	$34.19M	$30.00M
Receivables	$3.24M	$5.63M	$6.16M	$7.58M
Inventory	$882.00K	$3.31M	$4.72M	$4.66M
Current Assets	$100.26M	$68.35M	$98.08M	$61.21M
Total Assets	$146.07M	$124.16M	$158.41M	$118.47M
Current Liabilities	$14.91M	$14.44M	$21.53M	$48.96M
Long-Term Debt	$8.19M	$8.37M	$18.73M	$16.07M
Total Debt	$11.88M	$12.70M	$22.65M	$40.48M
Total Liabilities	$25.75M	$26.14M	$45.15M	$69.34M
Retained Earnings	-$118.21M	-$160.83M	-$217.74M	-$306.03M
Shareholders' Equity	$120.32M	$98.02M	$113.25M	$49.13M
Working Capital	$85.35M	$53.91M	$76.55M	$12.26M
Net Debt	—	—	—	$9.06M

NYXH Cash Flow statement, annual periods, in EUR
EUR	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$28.76M	-$44.78M	-$49.23M	-$68.98M
Capital Expenditure	-$16.35M	-$10.96M	-$6.07M	-$3.77M
Free Cash Flow	-$45.10M	-$55.74M	-$55.30M	-$72.75M
Depreciation & Amortisation	$1.93M	$2.36M	$2.72M	$4.48M
Stock-Based Compensation	$2.70M	$2.61M	$3.97M	$4.89M
Investing Cash Flow	-$89.95M	$32.01M	-$16.32M	$28.33M
Financing Cash Flow	-$983.00K	$16.86M	$77.44M	$38.11M
Dividends Paid	$0.00	$0.00	$0.00	$0.00
Net Change in Cash	-$119.69M	$4.09M	$11.89M	-$2.54M

NYXH Income statement, quarterly periods, in EUR
EUR	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$1.06M	$1.34M	$1.97M	$5.64M	$6.37M	$7.67M
Cost of Revenue	$406.00K	$490.00K	$779.00K	$2.02M	$2.73M	$3.09M
Gross Profit	$658.00K	$850.00K	$1.19M	$3.63M	$3.64M	$4.58M
Research & Development	$8.99M	$10.06M	$12.91M	$10.87M	$8.80M	$9.54M
Selling, General & Admin	$12.03M	$10.32M	$12.12M	$11.98M	$14.94M	$15.24M
Operating Expenses	$21.30M	$20.70M	$25.39M	$21.88M	$24.14M	$25.13M
Operating Income	-$20.64M	-$19.85M	-$24.20M	-$18.26M	-$20.50M	-$20.55M
EBITDA	-$20.79M	-$18.88M	-$21.73M	-$21.34M	-$12.40M	-$21.44M
Pretax Income	-$22.26M	-$20.33M	-$23.87M	-$22.62M	-$15.55M	-$32.49M
Income Tax	$125.00K	$278.00K	-$290.00K	$895.00K	$390.00K	$477.00K
Net Income	-$22.38M	-$20.61M	-$23.58M	-$23.51M	-$15.94M	-$32.96M
Diluted EPS	-0.60	-0.55	-0.63	-0.59	-0.37	-0.58
Diluted Shares	37.43M	37.43M	37.45M	40.12M	43.23M	57.01M

NYXH Balance Sheet statement, quarterly periods, in EUR
EUR	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$22.39M	$22.73M	$10.87M	$30.00M	$12.93M	$64.11M
Receivables	$5.46M	$5.65M	$4.50M	$7.58M	$8.82M	$9.95M
Inventory	$4.98M	$5.33M	$6.08M	$4.66M	$4.35M	$3.71M
Current Assets	$75.21M	$55.11M	$35.34M	$61.21M	$40.57M	$112.67M
Total Assets	$135.90M	$116.47M	$93.60M	$118.47M	$97.60M	$168.47M
Current Liabilities	$20.97M	$20.95M	$20.76M	$48.96M	$41.06M	$47.27M
Long-Term Debt	$15.87M	$16.23M	$17.10M	$16.07M	$16.43M	$27.56M
Total Debt	$19.44M	$19.71M	$19.47M	$40.48M	$35.08M	$52.57M
Total Liabilities	$43.06M	$43.07M	$42.65M	$69.34M	$61.73M	$85.36M
Retained Earnings	-$240.10M	-$260.21M	-$282.79M	-$306.03M	-$321.73M	-$353.57M
Shareholders' Equity	$92.84M	$73.40M	$50.95M	$49.13M	$35.87M	$83.11M
Working Capital	$54.24M	$34.17M	$14.59M	$12.26M	-$491.00K	$65.41M
Net Debt	—	—	$6.48M	$9.06M	$19.97M	—

NYXH Cash Flow statement, quarterly periods, in EUR
EUR	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	-$18.52M	-$16.73M	-$20.48M	-$13.24M	-$21.55M	-$16.57M
Capital Expenditure	-$1.07M	-$1.24M	-$227.00K	-$1.23M	-$883.00K	-$1.28M
Free Cash Flow	-$19.60M	-$17.97M	-$20.71M	-$14.47M	-$22.44M	-$17.86M
Depreciation & Amortisation	$774.00K	$774.00K	$1.44M	$1.50M	$1.72M	$1.81M
Stock-Based Compensation	$1.98M	$885.00K	$1.12M	$903.00K	$881.00K	$1.56M
Investing Cash Flow	$8.13M	$18.66M	$8.82M	-$7.28M	$4.60M	-$22.30M
Financing Cash Flow	-$730.00K	-$472.00K	-$305.00K	$39.61M	-$400.00K	$89.38M
Dividends Paid	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Net Change in Cash	-$11.12M	$1.45M	-$11.97M	$19.10M	-$17.35M	$50.51M

Market Snapshot

About

Nyxoah is a Belgium-based medical technology company developing innovative neurostimulation therapy for obstructive sleep apnea. The company's lead product is a bilateral hypoglossal nerve stimulation system that treats moderate to severe sleep apnea.